FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
MAIA Biotechnology, Inc. Stock AnalysisComprehensive stock analysis for MAIA Biotechnology, Inc. (MAIA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMAIA
MAIA
MAIA Biotechnology, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MAIA
Home🔹Stocks🔹MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc.

🇺🇸MAIA•AMEX

MAIA Biotechnology, Inc.

🇺🇸MAIA•AMEX
Market cap
$79.04M
Sentiment

Your view on MAIA

Mkt Cap
$79.04M
Sentiment
Your view
MAIA
MAIA Biotechnology, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MAIA
Company Overview

Overview

What the company does, where it operates, and who runs it.

About MAIA Biotechnology, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Vlad Vitoc
Headquarters
444 West Lake Street, Chicago, IL, US
Industry
Biotechnology
Sector
Healthcare
CEO
Vlad Vitoc
Headquarters
444 West Lake Street, Chicago, IL, US
Description

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity.

The company was founded in 2018 and is headquartered in Chicago, Illinois.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for MAIA Biotechnology, Inc., and the rating behind it. MAIA last traded at $1.30; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for MAIA Biotechnology, Inc.. Starting points for MAIA Biotechnology, Inc.: EPS -$0.44, beta 0.26 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for MAIA Biotechnology, Inc.. MAIA Biotechnology, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for MAIA Biotechnology, Inc.. Trailing twelve-month EPS for MAIA Biotechnology, Inc. stands at -$0.44. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for MAIA Biotechnology, Inc.. MAIA Biotechnology, Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

MAIA Biotechnology, Inc. valued side by side against its closest peers. MAIA Biotechnology, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold MAIA Biotechnology, Inc., and how their positions are changing. At a $79.0M market value, institutional positions materially move MAIA Biotechnology, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by MAIA Biotechnology, Inc. executives and directors. Shares of MAIA Biotechnology, Inc. have traded between $0.98 and $2.74 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming MAIA Biotechnology, Inc.. MAIA Biotechnology, Inc. is a $79.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming MAIA Biotechnology, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for MAIA Biotechnology, Inc.. Coverage tracks MAIA Biotechnology, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • ANVS — Annovis Bio, Inc.
  • BCAB — BioAtla, Inc.
  • CALC — CalciMedica, Inc.
  • CELU — Celularity Inc.
  • ELUT — Elutia Inc.
  • LTRN — Lantern Pharma Inc.
  • PYPD — PolyPid Ltd.
  • RNXT — RenovoRx, Inc.

More Biotechnology companies

  • MSRM — Mushrooms Inc
  • MTNB — Matinas BioPharma Holdings, Inc.
  • MTVA — MetaVia Inc.
  • MXCT — MaxCyte, Inc.
  • MYMX — Mymetics Corporation
  • MYNDF — MYND Life Sciences Inc.
  • NAGE — Niagen Bioscience Inc
  • NAMS — NewAmsterdam Pharma Company N.V.
  • NAMSW — NewAmsterdam Pharma Company N.V.
  • NAUT — Nautilus Biotechnology, Inc.
  • NAVBQ — Navidea Biopharmaceuticals, Inc.
  • NBIO — Nascent Biotech, Inc.

ETFs holding MAIA Biotechnology, Inc.

  • IWC — iShares Micro-Cap ETF (0.02%)
  • VXF — Vanguard Extended Market ETF (0.00%)
  • VUS.TO — Vanguard U.S. Total Market Index ETF (CAD-hedged) (0.00%)
  • VUN.TO — Vanguard U.S. Total Market Index ETF (0.00%)
  • VTS.AX — Vanguard U.S. Total Market Shares Index ETF (0.00%)
  • VTI — Vanguard Total Stock Market ETF (0.00%)

News

Latest Market News